US Stock MarketDetailed Quotes

EBS Emergent BioSolutions

Watchlist

10.740
+2.080+24.02%

Close Aug 16 16:00 ET

10.731
-0.009-0.08%

Post 19:59 ET

568.22MMarket Cap-957P/E (TTM)

Emergent BioSolutions Stock Forum

InfiltradeR

17 hours ago

$Emergent BioSolutions (EBS.US)$ Bavarian Nordic ramping up production to hit 10 mil doses by end of 2025. We're still severely short on vaccines, don't you think?
Africa is currently facing a shortage of supply of mpox vaccines. Africa CDC estimates that currently about 200,000 doses are available compared to a requirement of at least 10 million doses, based on estimates from countries that have prepared vaccination plans.
----------------------------------------------
Danish biotech firm Bava...

InfiltradeR

Yesterday 17:24

$Emergent BioSolutions (EBS.US)$ Price difference between Jyyneos vs ACAM2000.
The World Health Organization (WHO) appealed for support this week by declaring the latest mpox outbreak in Africa an international health emergency. Trouble is, there are scant funds currently available to tackle the potentially lethal virus.
Jynneos
Approximate Cost: $110 to $120 per dose.
Dosing: Typically administered in a two-dose regimen, so the total cost per person would be around $220 to $240.
ACAM2000
Appro...

InfiltradeR

Yesterday 16:06

$Emergent BioSolutions (EBS.US)$ Efficacy of ACAM2000 vs JYYNEOS against MPOX.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120163/

InfiltradeR

Yesterday 15:11

$Emergent BioSolutions (EBS.US)$ A new lethal strain of the mpox virus could already have made its way to the UK, an expert has warned. Leading professor Paul Hunter said the country could begin seeing cases in the next two weeks, as fears over the strain increase.
https://www.google.com/amp/s/www.manchestereveningnews.co.uk/news/uk-news/new-mpox-strain-likely-already-29756873.amp

scarlight : Well hope EBS medicine will get approved soon. Another pandemic would be terrible for everyone.

Report
Reply

Cancel Reply
InfiltradeR OP scarlight : ACAM2000 vaccine
ACAM2000 is a live-attenuated smallpox vaccine that is also effective against mpox. ACAM2000 is manufactured by Emergent BioSolutions.
Administration of ACAM2000 requires specialised training and facilities.
ACAM2000 is not suitable for:
. severely immunocompromised people
. people who are pregnant or breastfeeding
. people with cardiac disease or cardiac risk factors
. people with active eczema
. infants below 12 months of age.
ACAM2000 is registered with the Therapeutic Goods Administration (TGA) for use in Australia. Visit the TGA website for more consumer information and product information about ACAM2000.
Vaccine availability and access
There is a globally limited supply of the JYNNEOS® vaccine and high international demand.
The Australian Government, in conjunction with states and territories, has secured an initial supply of JYNNEOS® and is working with the manufacturer to secure more.
Given vaccine supply is limited, access to vaccines will initially be prioritised to support strong outbreak management, and this may include those who are:
Close physical contacts of people infected with mpox, such as intimate partners and people who live in the same household.
Population groups who might be at higher risk of exposure or further transmission, such as gay, bisexual, or other men who have sex with men who have a high number of sexual contacts or are travelling to countries where mpox is present, or those where mpox is more likely to result in serious illness.
People whose occupations might put them at increased risk, including laboratory staff and healthcare workers.

Report
Reply

Cancel Reply
InfiltradeR OP scarlight : There's limited supply for Jyyneos. Let's see how the situation progress.

Report
Reply

Cancel Reply

InfiltradeR

Yesterday 14:46

$Emergent BioSolutions (EBS.US)$ WHO: Mpox vaccine production must ramp up to combat deadly strain.
https://www.google.com/amp/s/www.malaymail.com/amp/news/world/2024/08/17/who-mpox-vaccine-production-must-ramp-up-to-combat-deadly-strain/147296

Green Dragon 2024

Yesterday 02:02

Monkey Pox stock thoughts

$Emergent BioSolutions (EBS.US)$ Besides the usual pump and dump and day trades. The monkeypox situation will intensify, especially with air travel and the changing seasons. The virus will spread more quickly in the coming months. As we have seen with Covid. Monkeypox cases are being reported every week in a new country. The government vaccine reserves will inevitably run out. I suggest people do an analysis of these stocks, BVNRY, EBS, GOVX, TNXP to help narrow down the ...